|Gliadel ®||carmustine, BCNU implant||Implant||7.7 mg; 8 wafers|
GLIADEL is indicated in newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation.
GLIADEL is also indicated for use as an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme (GBM) for whom surgical resection is indicated.
Glioblastoma multiforme, suspected or confirmed, at the time of initial surgery.
Note: Carmustine is not PBS-subsidised for use in conjunction with PBS-subsidised temozolomide.
|Information for Patients|
|Consumer Medicine Information||Gliadel_CMI|
|Information for Healthcare Professionals|